Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_assertion type Assertion NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_head.
- NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_assertion description "[First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_provenance.
- NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_assertion evidence source_evidence_literature NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_provenance.
- NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_assertion SIO_000772 22215754 NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_provenance.
- NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_assertion wasDerivedFrom befree-20140225 NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_provenance.
- NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_assertion wasGeneratedBy ECO_0000203 NP325916.RAUd61DuEzU9hJ_KgQ-Eobaldgq4sr17e3V6m-6aDHx5o130_provenance.